A European consortium has been awarded a grant of up to €1m to develop a blood-based multi-omics test to predict response to immune checkpoint inhibitors in cancer.
The collaboration is made up of Novigenix, PamGene International and Radboud University.
Immune checkpoint inhibitors (ICIs) have become one of the main treatments for patients with metastatic cancer. Although ICIs are highly effective with durable results in some patients, only a minority respond and benefit from ICIs.
The aim of the consortium is to develop a novel in vitro diagnostic (IVD) liquid biopsy test for accurate prediction of response to ICIs, leveraging a unique multi-omics approach of combining mRNA and kinase activity profiling.
The biomarker development strategy is based on whole blood transcriptome and kinome profiling technologies. The consortium will take advantage of advanced machine learning methods to develop and validate the AI-based multi-omics signatures.
Eurostars, which supports international innovative projects led by R&D-performing SMEs, is behind the funding.
Dr Brian Hashemi, executive chairman of Novigenix, said: “This Eurostars project combines excellent, world-leading science and technologies in a consortium dedicated to developing the first high performance multi-modal liquid biopsy test for the prediction of anti-PD1 response in UC patients.
“The high Eurostars review score placed the project in the top 5% of its peers, and we believe its completion can significantly improve